HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natrol Fiber, Cleansing Teas Headline New Product Launches

This article was originally published in The Tan Sheet

Executive Summary

Fiberlicious, a new easily dissolved high-fiber tea from Natrol, is one of several products the firm is rolling out for early summer.

You may also be interested in...



Natrol Growth Strategy: Fewer Products, More Research, Higher Earnings

Natrol will take a more cautious approach to product introductions in the coming year, focusing on fewer products and heightened consumer research, President & CEO Elliot Balbert stated

Natrol

FlexAnew TV ads to break Sept. 24 on network, syndicated channels. Spots will join ongoing print ads, sampling, in-store displays as part of roughly $3 mil. promotional spend. Glucosamine/chondroitin supplement for joint health, which launched in May, is available in nearly 25,000 retail stores nationwide, firm notes (1"The Tan Sheet" May 21, p. 6)

Senna

Oral Carcinogenicity Study of Senna results should be available for FDA review by March 2003, Purdue Pharma tells agency in April 16 letter. Sponsored by Novartis, Reckitt & Colman, Madaus AG and Purdue, study began in January 2000 and will be completed in January 2002, with "pathology to be completed by September 2002 and an audited, draft report expected October 2002," letter states. OTC laxative tentative final monograph lists senna as Category III (more data needed); FDA inquired about study's progress so it could establish a timetable for completion of rulemaking. Four firms agreed to conduct two-year study to obtain Category I (safe and effective) status for ingredient

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel